Gene Products, rev

• 

  Subject Areas on Research

  • A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques. 
  • A comparison of regulatory features in primate lentiviruses. 
  • A nuclear role for the Fragile X mental retardation protein. 
  • Amphibian transcription factor IIIA proteins contain a sequence element functionally equivalent to the nuclear export signal of human immunodeficiency virus type 1 Rev. 
  • An ancient family of human endogenous retroviruses encodes a functional homolog of the HIV-1 Rev protein. 
  • Assaying nuclear messenger RNA export in human cells. 
  • Comparative analysis of Rev function in human immunodeficiency virus types 1 and 2. 
  • Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. 
  • Conserved functional organization of the human immunodeficiency virus type 1 and visna virus Rev proteins. 
  • Effects of chimeric mutants of human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex on nucleolar targeting signals. 
  • Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus type 1 in cells. 
  • Functional comparison of the Rev trans-activators encoded by different primate immunodeficiency virus species. 
  • Functional consequences of natural sequence variation in the activation domain of HIV-1 Rev. 
  • Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. 
  • Generation of nuclease resistant circular RNA decoys for HIV-Tat and HIV-Rev by autocatalytic splicing. 
  • Generation of nuclease resistant circular RNA decoys for HIV-Tat and HIV-Rev by autocatalytic splicing. 
  • HIV-1 Rev promotes the nuclear export of unspliced and singly spliced RNAs in a mammalian cell-free export system. 
  • HIV-1 auxiliary proteins: making connections in a dying cell. 
  • HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. 
  • HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. 
  • Human immunodeficiency virus type 1 rev protein as a negative trans-regulator. 
  • Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein. 
  • Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins. 
  • Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. 
  • Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. 
  • Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element. 
  • Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1. 
  • Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. 
  • Mutational definition of functional domains within the Rev homolog encoded by human endogenous retrovirus K. 
  • Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. 
  • Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. 
  • Nuclear export of late HIV-1 mRNAs occurs via a cellular protein export pathway. 
  • Nuclear mRNA export: insights from virology. 
  • Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. 
  • Phosphorylation of the rev gene product of human immunodeficiency virus type 1. 
  • Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. 
  • Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. 
  • RNA-sequence-mediated gene regulation in HIV-1. 
  • Recruitment of the Crm1 nuclear export factor is sufficient to induce cytoplasmic expression of incompletely spliced human immunodeficiency virus mRNAs. 
  • Retroviruses as model systems for the study of nuclear RNA export pathways. 
  • Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. 
  • Rev and the fate of pre-mRNA in the nucleus: implications for the regulation of RNA processing in eukaryotes. 
  • Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques. 
  • Sequence requirements for Rev multimerization in vivo. 
  • Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. 
  • Structural and functional analysis of the visna virus Rev-response element. 
  • Structure-function analyses of the HTLV-I Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action. 
  • Subcellular localization of the human immunodeficiency virus trans-acting art gene product. 
  • The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. 
  • The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence. 
  • The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent nuclear localization signals. 
  • Trans-activating rev protein of the human immunodeficiency virus 1 interacts directly and specifically with its target RNA. 
  • Using retroviruses to study the nuclear export of mRNA. 
  • Visna virus encodes a post-transcriptional regulator of viral structural gene expression.